Clinical Trial Update: DPX-Survivac and Checkpoint Inhibitor in DLBCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating DPX-Survivac in combination with a checkpoint inhibitor for adult diffuse large B-cell lymphoma (DLBCL), completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Checkpoint inhibitor
• DPX-Survivac

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Adult Diffuse Large Cell Lymphoma, Recurrent | Phase 2 | Status: COMPLETED